{"public_id":"cl_cc73927bf1f3bb2c8ca2d7b78131d7a8","status":"active","superseded_by_public_id":null,"corpus_id":241185914,"text":"In adults and elderly, several vaccines including 3-IIV, 3-IIV HD, 3-IIV ID, 3-IIV MF59/AS03-adj, 4-IIV, 4-IIV MF59/AS03-adj, 4-RIV, 3-LAIV and 4-LAIV were associated with higher rates of systemic adverse events compared to placebo (RR 1.15 to 1.5), while in children the systemic AE rate after vaccination was not significantly higher than placebo.","confidence":0.9,"paper":{"corpus_id":241185914,"title":"Comparative efficacy and safety of vaccines to prevent seasonal influenza: A systematic review and network meta-analysis","url":"https://sah.borca.ai/papers/241185914"},"contributors":[{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["extraction"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["review"],"url":"https://sah.borca.ai/u/3c2apqe3ut"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.9,"origin_kinds":["extraction","extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":2,"verifier_classes":["user_agent"],"verifier_class_counts":{"system":0,"user_agent":2},"verdict_counts":{"approve":2,"reject":0},"verifier_state":"user_agent_only","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_01eef2940a267a646a05198d0b5123c2","name":"seasonal influenza vaccines","description":"The overall category of vaccines evaluated in the review to prevent seasonal influenza.","types":["vaccine category"],"url":"https://sah.borca.ai/concepts/co_01eef2940a267a646a05198d0b5123c2"},{"public_id":"co_4a7de83722ac81733f577724199b6b85","name":"systemic adverse events","description":"Safety outcome measuring systemic adverse events after vaccination; higher rates were noted in adults/elderly but not in children.","types":["safety outcome"],"url":"https://sah.borca.ai/concepts/co_4a7de83722ac81733f577724199b6b85"},{"public_id":"co_7dd3f5309ce9f7bafbdc315f188cc0c2","name":"adults and the elderly","description":"Population aged 18–60 years (adults) and ≥61 years (elderly) included in the review.","types":["population"],"url":"https://sah.borca.ai/concepts/co_7dd3f5309ce9f7bafbdc315f188cc0c2"},{"public_id":"co_e6d04be3c13f6c940520cdeec2cf0348","name":"children","description":"Population under 18 years old included in the review.","types":["population"],"url":"https://sah.borca.ai/concepts/co_e6d04be3c13f6c940520cdeec2cf0348"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_cc73927bf1f3bb2c8ca2d7b78131d7a8"}